An interventional study of GLUCOSAFE 2 and Local protocol control group with routine care in Critical Illness, Energy Supply; Deficiency, Severe and Protein Deficiency, sponsored by HEIDEGGER CP. Completed at 2 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-12.
Sponsored by HEIDEGGER CP · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The survival and the outcomes of critically ill patients are strongly influenced by insulin-therapy and nutritional support. The GLUCOSAFE 2 pilot study, aims to test the performance and the security of the new GLUCOSAFE 2 software, developed by the model-based medical decision support of Aalborg University (Denmark) and adapted to the clinical needs in the intensive care unit (ICU) of the Geneva University Hospital (HUG). This new device is based on a mathematical model of the glucose-insulin metabolism and attempts to give advices for better glycaemia control and nutritional therapy. The GLUCOSAFE 2 study hypothesizes that the use of the Glucosafe 2 software will allow better glycaemia ("Time-in-target") control and better achievement of nutritional energy and protein targets in comparison to the local protocols.
21 studies on the registry are indexed under Protein Deficiency; 4 are open to participants now.
This study's enrollment of 213 is above the median of 71 across 18 interventional studies indexed under Protein Deficiency.
Browse Protein Deficiency studies →HEIDEGGER CP is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Compared within Protein Deficiency, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All patients ≥ 18 years admitted to the ICU with
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Insulin-therapy and nutrition support guided by the GLUCOSAFE 2 software.
Device: GLUCOSAFE 2
Insulin-therapy and nutrition support guided by the local protocols (electronic or paper version) of the ICU/HUG.
Device: Local protocol control group with routine care
Retrospective data with standard care before the beginning of the pilot study in order to minimize the "cross-over" effect due to the fact that caregivers are going to have in charge patients in both groups (intervention and control group) at the same time.
Device: Historical control group with routine care
Use of GLUCOSAFE 2 software for nutrition management and insulin-therapy
Use of the local protocols (electronic or paper version) for nutrition management and blood glucose control.
Use of the local protocols (electronic or paper version) for nutrition management and blood glucose control.
Time-in-target (range: 5.0 - 8.5 mmol/l)
Time spent in the glycaemia range of 5.0 - 8.5 mmol/l per day, per patient and in the cohort
Time frame: During ICU stay, up to 15 days post-randomization.
Overall number of mild (<3.3 mmol/l) and severe (<2.2 mmol/l) hypoglycemia events
Overall number of mild (\<3.3 mmol/l) and severe (\<2.2 mmol/l) hypoglycemia events (per patient and in the cohort)
Time frame: During ICU stay, up to 15 days post-randomization.
Overall percentage of mild (<3.3 mmol/l) and severe (<2.2 mmol/l) hypoglycemia events
Overall percentage of mild (\<3.3 mmol/l) and severe (\<2.2 mmol/l) hypoglycemia events (per patient and in the cohort)
Time frame: During ICU stay, up to 15 days post-randomization.
Number of mild (<3.3 mmol/l) and severe (<2.2 mmol/l) hypoglycemia events due to non-compliance
Overall number of mild (\<3.3 mmol/l) and severe (\<2.2 mmol/l) hypoglycemia events due to non-compliance (only in intervention arm)
Time frame: During ICU stay, up to 15 days post-randomization.
Percentage of mild (<3.3 mmol/l) and severe (<2.2 mmol/l) hypoglycemia events due to non-compliance
Percentage of mild (\<3.3 mmol/l) and severe (\<2.2 mmol/l) hypoglycemia events due to non-compliance (only in intervention arm)
Time frame: During ICU stay, up to 15 days post-randomization.
Time to normalize blood glucose (5.0-8.5 mmol/l)
Three values \< 8.5 mmol/l as indicator for normalization
Time frame: During ICU stay, up to 15 days post-randomization.
Percentage of time in the ICU (per patient and in the cohort) with hyperglycaemia (BG > 8.5 mmol/l)
Percentage of time with BG \> 8.5 mmol/l before and after normalization per patient and in the cohort.
Time frame: During ICU stay, up to 15 days post-randomization.
Percentage of time in the ICU (per patient and in the cohort) with hyperglycaemia (BG > 8.5 mmol/l) due to non compliance
Percentage of time with BG \> 8.5 mmol/l before and after normalization per patient and in the cohort due to non compliance (only in the intervention arm).
Time frame: During ICU stay, up to 15 days post-randomization.
Number of hyperglycemic episodes after normalization (> 8.5 mmol/l)
Three values \< 8.5 mmol/h as indicator for normalization
Time frame: From normalization time during ICU stay, up to 15 days post-randomization.
Number of hyperglycemic episodes after normalization (> 8.5 mmol/l) due to non compliance
Three values \< 8.5 mmol/h as indicator for normalization
Time frame: From normalization time during ICU stay, up to 15 days post-randomization.
Number of episodes (per patient and in the cohort) where a BG measurements is not followed up within 30 minutes by a request for Glucosafe 2 advice
Number of episodes (per patient and in the cohort) where a BG measurements is not followed up within 30 minutes by a request for Glucosafe 2 advice
Time frame: During ICU stay, up to 15 days post-randomization.
Number of episodes (per patient and in the cohort) where pumps were not set within 30 min according to Glucosafe2 advice accepted by the nurse.
Number of episodes (per patient and in the cohort) when pumps were not set within 30 min according to Glucosafe2 advice accepted by the nurse.
Time frame: During ICU stay, up to 15 days post-randomization.
Number of advices given by GS2 which were accepted, accepted with modification, or rejected.
Number of advices given by GS2 which were accepted, accepted with modification, or rejected.
Time frame: During ICU stay, up to 15 days post-randomization.
Frequency of daily and cumulated BG measurements per patient and in the cohort
Frequency of BG measurements (per patient and in the cohort)
Time frame: During ICU stay, up to 15 days post-randomization.
Frequency of daily and cumulated adjustments of insulin and nutrition pump settings (per patient and in the cohort)
Frequency of daily and cumulated adjustments of insulin and nutrition pump settings (per patient and in the cohort)
Time frame: During ICU stay, up to 15 days post-randomization.
Glycaemic variability
Mean and standard deviation (SD) of blood glucose measurements. Daily maximum blood glucose difference.
Time frame: During ICU stay, up to 15 days post-randomization.
Protein goal achievements (80-100% of accumulated target) with a target of 1.3 g/kg of body weight per day.
Percentage of proteins received per day and at the end of the ICU stay with a target of 1.3 g/kg of body weight per day.
Time frame: During ICU stay, up to 15 days post-randomization.
Caloric goal achievements (80-100% of the accumulated target) by indirect calorimetry (IC) or predictive formula if IC not feasible.
Percentage of nutritional and non-nutritional calories received per day and at the end of the ICU stay with a target defined by IC or predictive formula if IC not feasible.
Time frame: During ICU stay, up to 15 days post-randomization.
Energy debt: difference between the defined energy target (80-100%, defined by IC or predictive formula) and the energy received (nutritional and non-nutritional)
Per day and at the end of the ICU stay.
Time frame: During ICU stay, up to 15 days post-randomization.
Protein debt: difference between the defined protein target (1.3 g/kg of body weight/day) and the proteins received
Per day and at the end of the ICU stay.
Time frame: During ICU stay, up to 15 days post-randomization.
Prediction of BG
Prediction error as a function of time elapsed since last BG measurement, per patient, per cohort.measurement (per patient and per cohort).
Time frame: During ICU stay, up to 15 days post-randomization.
Plan to share: Undecided
Ran from Jan 2023 to primary completion in Jan 2025, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
HEIDEGGER CP